Synergistic interactions between imatinib mesylate and the novel phosphoinositide-dependent kinase-1 inhibitor OSU-03012 in overcoming imatinib mesylate resistance

Resistance to the Ableson protein tyrosine (Abl) kinase inhibitor imatinib mesylate has become a critical issue for patients in advanced phases of chronic myelogenous leukemia. Imatinib-resistant tumor cells develop, in part, as a result of point mutations within the Abl kinase domain. As protein ki...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Tseng, Ping-Hui, Lin, Ho-Pi, Zhu, Jiuxiang, Chen, Kuen-Feng, Hade, Erinn M., Young, Donn C., Byrd, John C., Grever, Michael, Johnson, Kara, Druker, Brian J., Chen, Ching-Shih
Médium: Artigo
Jazyk:Inglês
Vydáno: © 2005 by The American Society of Hematology 2005
Témata:
Neoplasia
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC1895085/
https://ncbi.nlm.nih.gov/pubmed/15665113
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2004-07-2967
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky